Becton, Dickinson and Company (NYSE:BDX) Releases FY24 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) updated its FY24 earnings guidance on Thursday. The company provided earnings per share guidance of $12.95-13.15 for the period, compared to the consensus earnings per share estimate of $12.95. The company issued revenue guidance of ~$20.1-20.3 billion, compared to the consensus revenue estimate of $20.30 billion.

Analysts Set New Price Targets

Separately, Barclays increased their price target on Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an overweight rating in a research note on Monday, February 5th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of Moderate Buy and an average price target of $280.00.

Becton, Dickinson and Company Trading Down 2.4 %

Shares of Becton, Dickinson and Company stock traded down $5.67 during trading on Friday, hitting $234.68. The company’s stock had a trading volume of 1,722,353 shares, compared to its average volume of 1,291,373. The stock has a market cap of $67.80 billion, a price-to-earnings ratio of 51.69, a price-to-earnings-growth ratio of 1.93 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.64. Becton, Dickinson and Company has a 52 week low of $229.40 and a 52 week high of $287.32. The stock has a 50-day moving average price of $238.45 and a two-hundred day moving average price of $240.53.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.97 by $0.20. The firm had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.86 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post 13.04 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be given a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.62%. Becton, Dickinson and Company’s payout ratio is presently 83.70%.

Insiders Place Their Bets

In related news, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the transaction, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the transaction, the senior vice president now directly owns 2,276 shares in the company, valued at $542,348.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the sale, the executive vice president now owns 5,381 shares in the company, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. Corporate insiders own 0.31% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.